Regulatory and Policy Trends Affecting Life Sciences

With market demand for blockbusters and breakthroughs competing with increasingly coordinated regulatory regimes and emboldened plaintiff counsel, leading pharmaceutical, medical device, biotech, and health tech firms are entering a heightened phase of operation across their product life cycle.

The following analyses—authored by attorneys in our nationally recognized Life Sciences group and Law360 Healthcare Practice Group of the Year, among others—cover a range of both the large-scale proposals and ongoing micro-measures that are likely to affect life sciences companies in their domestic and international efforts to promote and protect the value of their discoveries.

Email Disclaimer